Study population characteristics according to inhibitor status and ITI treatment among people with severe hemophilia A
| Categories . | Participants with, and without, an inhibitor . | ITI treatment among participants with an inhibitor . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total . | No inhibitor . | Inhibitor . | Inhibitor vs no inhibitor . | No ITI . | ITI . | ITI vs no ITI . | Failed . | Partially successful . | Successful . | Successful vs partial vs failed . | |
| N = 3659 . | n = 3086 . | n = 576 . | P value . | n = 70 . | n = 485 . | P value . | n = 91 . | n = 95 . | n = 299 . | P value . | |
| n (%) | |||||||||||
| Race/ethnicity∗ | <.001 | .71 | .009 | ||||||||
| Asian | 173 (4.8) | 145 (4.8) | 30 (5.3) | † | 24 (5) | 6 (6.6) | † | 14 (4.7) | |||
| Black | 529 (14.6) | 415 (13.6) | 115 (20.2) | 15 (21.4) | 95 (19.8) | 17 (18.7) | 25 (26.9) | 53 (18.0) | |||
| Hispanic | 540 (14.9) | 437 (14.3) | 102 (17.9) | 15 (21.4) | 83 (17.3) | 20 (22) | 14 (15.1) | 49 (16.6) | |||
| White | 2350 (65) | 2031 (66.6) | 321 (56.3) | 36 (51.4) | 275 (57.4) | 48 (52.7) | 50 (53.8) | 177 (60.0) | |||
| Insurance | .002 | <.001 | < .001 | ||||||||
| Commercial | 1862 (52) | 1601 (53) | 260 (45.9) | 22 (32.4) | 231 (48.2) | 39 (43.3) | 48 (51.1) | 144 (48.8) | |||
| Medicaid | 1209 (33.7) | 979 (32.4) | 227 (40) | 22 (32.4) | 200 (41.8) | 40 (44.4) | 44 (46.8) | 116 (39.3) | |||
| Medicare | 313 (8.7) | 265 (8.8) | 53 (9.3) | 19 (27.9) | 28 (5.8) | † | † | 20 (6.8) | |||
| Other | 199 (5.6) | 173 (5.7) | 27 (4.8) | † | 20 (4.2) | † | † | 15 (5.1) | |||
| HIV | 424 (12) | 395 (13.2) | 31 (5.5) | <.001 | 13 (19.7) | 16 (3.4) | <.001 | † | † | 10 (3.4) | < .001 |
| HCV | 1039 (29.2) | 915 (30.5) | 135 (24) | .001 | 40 (59.7) | 82 (17.2) | <.001 | 18 (20) | 10 (10.9) | 54 (18.3) | < .001 |
| Prophylaxis‡ | 3085 (84.3) | 2451 (79.5) | 412 (71.5) | <.001 | 32 (35.2) | 380 (78.4) | <.001 | 40 (44.0) | 74 (77.9) | 266 (89.0) | < .001 |
| Median (IQR) | |||||||||||
| Age at enrollment, y | 21 (13-33) | 22 (13-34) | 19 (12-28) | <.001 | 34 (19-52) | 18 (12-26) | <.001 | 19 (11-28) | 17 (10-23) | 18 (12-26) | .068 |
| Age of inhibitor detection, y | -- | -- | 1.8 (1-4.5) | -- | 6 (2.2- 22) | 1.7 (1- 3.8) | <.001 | 1.6 (0.9-4.2) | 1.2 (0.8-2.3) | 1.8 (1-3.8) | .351 |
| Categories . | Participants with, and without, an inhibitor . | ITI treatment among participants with an inhibitor . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total . | No inhibitor . | Inhibitor . | Inhibitor vs no inhibitor . | No ITI . | ITI . | ITI vs no ITI . | Failed . | Partially successful . | Successful . | Successful vs partial vs failed . | |
| N = 3659 . | n = 3086 . | n = 576 . | P value . | n = 70 . | n = 485 . | P value . | n = 91 . | n = 95 . | n = 299 . | P value . | |
| n (%) | |||||||||||
| Race/ethnicity∗ | <.001 | .71 | .009 | ||||||||
| Asian | 173 (4.8) | 145 (4.8) | 30 (5.3) | † | 24 (5) | 6 (6.6) | † | 14 (4.7) | |||
| Black | 529 (14.6) | 415 (13.6) | 115 (20.2) | 15 (21.4) | 95 (19.8) | 17 (18.7) | 25 (26.9) | 53 (18.0) | |||
| Hispanic | 540 (14.9) | 437 (14.3) | 102 (17.9) | 15 (21.4) | 83 (17.3) | 20 (22) | 14 (15.1) | 49 (16.6) | |||
| White | 2350 (65) | 2031 (66.6) | 321 (56.3) | 36 (51.4) | 275 (57.4) | 48 (52.7) | 50 (53.8) | 177 (60.0) | |||
| Insurance | .002 | <.001 | < .001 | ||||||||
| Commercial | 1862 (52) | 1601 (53) | 260 (45.9) | 22 (32.4) | 231 (48.2) | 39 (43.3) | 48 (51.1) | 144 (48.8) | |||
| Medicaid | 1209 (33.7) | 979 (32.4) | 227 (40) | 22 (32.4) | 200 (41.8) | 40 (44.4) | 44 (46.8) | 116 (39.3) | |||
| Medicare | 313 (8.7) | 265 (8.8) | 53 (9.3) | 19 (27.9) | 28 (5.8) | † | † | 20 (6.8) | |||
| Other | 199 (5.6) | 173 (5.7) | 27 (4.8) | † | 20 (4.2) | † | † | 15 (5.1) | |||
| HIV | 424 (12) | 395 (13.2) | 31 (5.5) | <.001 | 13 (19.7) | 16 (3.4) | <.001 | † | † | 10 (3.4) | < .001 |
| HCV | 1039 (29.2) | 915 (30.5) | 135 (24) | .001 | 40 (59.7) | 82 (17.2) | <.001 | 18 (20) | 10 (10.9) | 54 (18.3) | < .001 |
| Prophylaxis‡ | 3085 (84.3) | 2451 (79.5) | 412 (71.5) | <.001 | 32 (35.2) | 380 (78.4) | <.001 | 40 (44.0) | 74 (77.9) | 266 (89.0) | < .001 |
| Median (IQR) | |||||||||||
| Age at enrollment, y | 21 (13-33) | 22 (13-34) | 19 (12-28) | <.001 | 34 (19-52) | 18 (12-26) | <.001 | 19 (11-28) | 17 (10-23) | 18 (12-26) | .068 |
| Age of inhibitor detection, y | -- | -- | 1.8 (1-4.5) | -- | 6 (2.2- 22) | 1.7 (1- 3.8) | <.001 | 1.6 (0.9-4.2) | 1.2 (0.8-2.3) | 1.8 (1-3.8) | .351 |
Data were collected from the CC registry between 2013 to 2017. The following number of patients were missing data on race/ethnicity (n = 44); insurance (n = 77); HIV infection (n = 114); HCV infection (n = 99).
“Other” race/ethnicities are “non-Hispanic,” and data are not included because of small sample sizes.
Data suppressed because of small sample sizes of <5.
Continuous prophylaxis as reported by the HTC.